Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Neuro-Oncology|May 12, 2016
Toca 511 plus 5-fluorocytosine in combination with lomustine shows chemotoxic and immunotherapeutic activity with no additive toxicity in rodent glioblastoma modelsKader Yagiz, Tiffany T Huang, Fernando Lopez Espinoza, et al.
Molecular Therapy. Nucleic Acids|March 23, 2017
Retroviral Replicating Vector Delivery of miR-PDL1 Inhibits Immune Checkpoint PDL1 and Enhances Immune Responses In VitroAmy H Lin, Christopher G Twitty, Ryan Burnett, et al.
Neuro-Oncology|April 8, 2017
Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma modelLeah A Mitchell, Fernando Lopez Espinoza, Daniel Mendoza, et al.
Human Gene Therapy|December 9, 2017
Efficient Therapeutic Protein Expression Using Retroviral Replicating Vector with 2A Peptide in Cancer ModelsAndrew Hofacre, Kader Yagiz, Daniel Mendoza, et al.
Molecular Therapy Oncolytics|January 12, 2018
A Retroviral Replicating Vector Encoding Cytosine Deaminase and 5-FC Induces Immune Memory in Metastatic Colorectal Cancer ModelsKader Yagiz, Maria E Rodriguez-Aguirre, Fernando Lopez Espinoza, et al.
Human Gene Therapy|November 25, 2014
Intravenous administration of retroviral replicating vector, Toca 511, demonstrates therapeutic efficacy in orthotopic immune-competent mouse glioma modelTiffany T Huang, Shraddha Parab, Ryan Burnett, et al.
Oncotarget|May 2, 2019
PD-L1 checkpoint blockade delivered by retroviral replicating vector confers anti-tumor efficacy in murine tumor modelsLeah A Mitchell, Kader Yagiz, Andrew Hofacre, et al.
Neuro-Oncology|November 11, 2011
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vectorDerek Ostertag, Karin K Amundson, Fernando Lopez Espinoza, et al.
Pageof 1